- Home
- YSG vs CNTX Comparison
YSG vs CNTX Comparison
Compare YSG & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | CNTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.5M | 283.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YSG | CNTX |
|---|---|---|
| Price | $2.80 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 109.3K | ★ 897.8K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.64 | $0.49 |
| 52 Week High | $11.04 | $3.62 |
Technical Indicators
Market Signals| Indicator | YSG | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 44.87 |
| Support Level | N/A | $2.07 |
| Resistance Level | $3.36 | $2.58 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 22.22 | 34.65 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.